Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma - Sorbonne Université
Article Dans Une Revue Future Oncology Année : 2021

Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma

Patrick Daniele
  • Fonction : Auteur
  • PersonId : 1120116
Dimitrios Tomaras
  • Fonction : Auteur
Gabriel Tremblay
Brian T Hill
  • Fonction : Auteur
Ronit Gurion
  • Fonction : Auteur
Sameer Bakhshi
  • Fonction : Auteur
Miklós Egyed
  • Fonction : Auteur
Priyanka Samal
  • Fonction : Auteur

Résumé

Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therapy (FACT) – Lymphoma and EuroQoL five-dimensions five-levels data collected in the single-arm Phase IIb trial SADAL (NCT02227251) were analyzed with mixed-effects models. Results: Treatment responders maintained higher FACT – Lymphoma (p ≤ 0.05), FACT – General (p < 0.05) and EuroQoL five-dimensions five-levels index scores (p < 0.001) beginning in cycle 3. The estimated difference in health state utilities for treatment response and progressive disease was both statistically significant and clinically meaningful (mean difference: 0.07; p = 0.001). Conclusion: In patients with relapsed/refractory diffuse large B-cell lymphoma, objective response to selinexor was associated with HRQoL maintenance, reduction in disease-related HRQoL decrements and higher health utilities.
Fichier principal
Vignette du fichier
fon-2020-0946.pdf (1.64 Mo) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-03476648 , version 1 (13-12-2021)

Identifiants

Citer

Jatin Shah, Sharon Shacham, Michael Kauffman, Patrick Daniele, Dimitrios Tomaras, et al.. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma. Future Oncology, 2021, 17 (11), pp.1295-1310. ⟨10.2217/fon-2020-0946⟩. ⟨hal-03476648⟩
22 Consultations
29 Téléchargements

Altmetric

Partager

More